Abbott price target raised to $127 from $125 at Barclays

Barclays analyst Matt Miksic raised the firm’s price target on Abbott to $127 from $125 and keeps an Overweight rating on the shares. The company reported an "impressive" quarter, driven by double digit growth across its portfolio, with strong growth in diabetes, the analyst tells investors in a research note.